Effect of sodium-glucose linked transporter-2 inhibitors on diabetes mellitus type 2 management efficiency. Clinical discussion

• Krivosheeva A.A.
• Alexander S. Ametov

Abstract

Currently, the incidence of type 2 diabetes has become a global pandemic. SGLT 2 inhibitors - a new class of drugs that works independently of insulin, which makes this class perspective and a potential addition to the majority of drugs for the treatment of diabetes. The study EMPA-REG OUTCOME empagliflozin today is the only drug for the treatment of type 2 diabetes, which has demonstrated the ability to reduce the risk of cardiovascular disease and mortality from them.

The aim - to evaluate the effectiveness of diabetes control type 2 by the addition of the complex therapy of the drug from the group empagliflozin SGLT 2 inhibitors.

Material and methods. Examination of the patient with diabetes meLLitus type 2, and poor gLycemic controL. Lab tests, incLuding continuous monitoring of bLood gLucose, HoLter ECG monitoring and bLood pressure. Adding to the gLucose-Lowering drug therapy empagLifLozin. The duration of treatment and monitoring of patients was 3 months, and then carried out a controL examination of the patient is stiLL the pLan.

Results. After 3 months of combined therapy with the drug empagLifLozin noted positive dinamika - reduction of 4 kg body weight, reduction in gLycemic variabiLity, improved gLycemic controL, reduction of HbA_1c.

Conclusions. Thus, adding empagLifLozina to therapy in patients with type 2 diabetes contributes to the eLimination of gLucose toxicity improve gLycemic controL.

Keywords:сахарный диабет типа 2, эмпаглифлозин, непрерывное мониторирование глюкозы крови, клинический разбор

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)